Galderma, a Swiss pharmaceutical giant, is capitalizing on the growing popularity of weight-loss drugs like Ozempic to boost its facial fillers business. The CEO of the company believes that the Ozempic face phenomenon presents an opportunity for its products to counteract the gaunt look associated with rapid weight loss and aging.
According to one cosmetic dermatologist, the Ozempic face is a result of aging and rapid weight loss which can lead to a sunken-in look in patients’ faces. Cosmetic dermatologist Dr. Paul Jarrod Frank, who coined the term, explains that this phenomenon occurs when the body loses fat in certain areas, such as around the cheeks and jawline, leading to a more youthful appearance.
Galderma has started a study to evaluate the effects of their products on patients who are using GLP-1 treatments like Ozempic. Enrollment for the study is ongoing and results may be available by the end of the year. The company creates skin care treatments and has products like Sculptra that are designed to counteract the gaunt look associated with the Ozempic face.
Dr. Joshua Zeichner, a dermatologist, has stated that he sees patients with complaints of the Ozempic face almost daily due to the widespread use of medications like Ozempic. Last month, Galderma went public on the SIX Swiss Exchange and reported a surge in shares. The company also reported a 12.4% increase year-over-year in sales, reaching $1 billion in the first quarter.
